Scholars Central

PerspectivePublished 2 May 2022

Cutaneous Small Vessel Vasculitis Due to Dolutegravir: A Rare Side Effect of Dolutegravir Based HAART Regimen in PLHIV

Authors: Cutaneous small-vessel vasculitis, Efavirenz-resistant virus, Cutaneous examination, Leukocytoclastic vasculitis

Journal of Vasculitis

Volume 8 · Issue 3 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

According to World Health Organization (WHO), Dolutegravir-based regimen is considered as first-line therapy for PLHIV and strongly recommended for all adults and children at the 10th International AIDS Society Conference on HIV Science (IAS 2019) held in Mexico City. Dolutegravir (integrase inhibitor) is pharmacokinetically favorable with a single daily dose, fewer drug interactions, superior potency against HIV-1, and potency against efavirenz-resistant virus. In 2020, NACO announced the phase-wise replacement of TLE regimen to TLD regimen.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Vasculitis.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Vasculitis
  • BylineArticles whose byline prints “Cutaneous small-vessel vasculitis”
  • BylineArticles whose byline prints “Efavirenz-resistant virus”
  • BylineArticles whose byline prints “Cutaneous examination”
  • BylineArticles whose byline prints “Leukocytoclastic vasculitis”